Hangzhou ACEA Pharmaceutical Research Co., Ltd.
Quick facts
Phase 3 pipeline
- Abivertinib Maleate Capsules · Oncology
Abivertinib is a tyrosine kinase inhibitor that targets mutant EGFR and other kinases involved in cancer cell proliferation. - Placebo Gefitinib Tablets · Oncology
Gefitinib is an epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor.
Competitive intelligence
For the full portfolio CI brief — phase mix, recent regulatory actions, upcoming PDUFA dates, patent timeline, class-overlap with competitors:
- Hangzhou ACEA Pharmaceutical Research Co., Ltd. portfolio CI brief
- Hangzhou ACEA Pharmaceutical Research Co., Ltd. pipeline updates RSS
Frequently asked questions about Hangzhou ACEA Pharmaceutical Research Co., Ltd.
What is Hangzhou ACEA Pharmaceutical Research Co., Ltd.'s pipeline?
Hangzhou ACEA Pharmaceutical Research Co., Ltd. has 2 drugs in Phase 3, 0 in Phase 2, 0 in Phase 1. Late-stage candidates include Abivertinib Maleate Capsules, Placebo Gefitinib Tablets.
Related
- Sector hub: All tracked pharma companies